How Investors Evaluate Human Capital At Deal Stage
The applications for artificial intelligence (AI) in healthcare continue to expand, as evidenced by the proliferation of AI use cases across all segments of the industry, as well as by the explosion of start-ups focused on leveraging AI to address a broad array of challenges. A July 2020 survey conducted by Accenture reported that 69% of healthcare organizations are piloting or adopting AI solutions. We are seeing an infusion of AI in care delivery, RCM, process re-engineering, and also directly in the care setting with the development of highly sophisticated ambient sensors.
AI is at the dawn of a new era in healthcare and many organizations are experiencing impressive results as the power of technology enhances effectiveness and efficiency. In addition to the abundance of trade news on the topic, I’ve recently had the opportunity to discuss AI with innovative companies on the forefront of applying AI to healthcare and achieving validated results. A few highlights of my conversations and readings follow:
The universe of established players and new entrants in the AI space is extensive and broadening weekly with news of venture activity and M&A. We are at the forefront of the AI revolution in healthcare and expect continued innovation and disruption as the technology advances.